168 Chapter 7 Measure Distribution/ Event rate Estimated treatment effect Total n (β = 80% 2p = 0.05) S/F94 day 5 Mean = 2.38 SD = 1.31 ρ vs Day 0 = 0.42 Δ S/F94: 0.177 1,430 S/F94 day 8 Mean = 2.74 SD = 1.53 ρ vs Day 0 = 0.39 Δ S/F94: 0.153 2.696 WHO day 5 4: 1,979/8,270 5: 1,861/8,270 6: 2,270/8,270 7: 301/8,270 8: 980/8,270 9: 313/8,270 10: 566/8,270 Proportional odds ratio: 0.84 3,293 WHO day 8 4: 2,478/6,916 5: 1,206/6,916 6: 1,196/6,916 7: 361/6,916 8: 812/6,916 9: 261/6,916 10: 602/6,916 Proportional odds ratio: 0.84 3,227 1-level sustained improvement 12,057/26,854 (44.9%) Risk ratio: 1.03 6,544 2-level sustained improvement 4,914/26,854 (18.3%) Risk ratio: 1.04 3,722 28-day mortality 7,583/36,559 (20.7%) Risk ratio: 0.85 5,154 Supplementary Table 2. Comparison of outcome measures among 36,559 hospitalised patients aged 20-75, who required supplemental oxygen on the day of admission. The estimated treatment effect is for a 15% relative reduction in mortality. For S/F94, the mean value and standard deviation (SD) and the correlation with S/F94 on day 0 are reported for both day 5 and day 8. For the WHO ordinal severity scale, the number of people in each group between 4 (hospitalised, no oxygen support) and 10 (dead) are reported. For 1- and 2-level sustained improvement, the number of people reaching sustained improvement is reported. For 28day mortality, the proportion of patients who died at day 28 is reported. Sample sizes shows the total number of subjects needed in both arms using a 1:1 allocation.
RkJQdWJsaXNoZXIy MTk4NDMw